Re: Pattern of recurrence of early bc differs by intrinsic subtype & proliferation in
I like the idea of the booster.
After looking at Hopeful's prior conversation I see perhaps two higher risk times, one about a 2-2 1/2 year interval, another at 5-6 years with ER+, Her2+.
I love the idea of the Herceptin injections as boosters. Do we really need a clinical trial? Almost all have had an entire year of Herceptin infusions. For stage 1-3 who remain as NED this has been for prevention. To receive an injection booster at 18 months, then 24 mths, 48 mths and 60 mths for ER+, Her2 patients should be something left to the discretion of the oncologist and patient.
"Modern" medicine will never achieve personalized care if the FDA has to approve & micromanage everything based on clinical trials for the good of the group, and not the individual.
Last edited by 'lizbeth; 10-24-2013 at 10:54 AM..
Reason: typo(s)
|